Filana Therapeutics Inc (FLNA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$0.64-2.84%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Filana Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.265
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-0.895
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-1.19

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Net cash used in operations stays below $17 million in H1 2026	Filana aims to limit cash use to $17 million in H1 2026.	Broken	Net cash used in operations exceeds $17 million in H1 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 quarters (2025-Q4, 2026-Q1, 2026-Q2). Net cash used in operations was $8.9M in 2026-Q1 and $12.7M in first-half 2026, below prior guidance. Management guides $11M to $15M net cash use for second-half 2026. The trajectory shows controlled cash use consistent with management's stated cost discipline. Delivery assessment Oct 24, 2026
EPS loss narrows toward -$0.25 next quarter	A supporting condition in Filana Therapeutics Inc's published investment case. The stated target is >=-0.25 USD_PER_SHARE.	Under Pressure	EPS loss worsens below -$0.25 next quarter	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage $31.25 million estimated loss from securities litigation	It plans to handle a $31.25 million loss from securities litigation.	Intact	Loss contingency rises above $31.25 million or unresolved by mid-2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 0
2026-07-25	Unavailable	Unavailable	1 / 0
2026-07-26	Unavailable	Unavailable	1 / 0
2026-07-27	Unavailable	Unavailable	1 / 0
2026-07-28	Unavailable	Unavailable	1 / 0
2026-07-29	Unavailable	Unavailable	1 / 0
2026-07-30	Unavailable	Unavailable	1 / 1
2026-07-31	Unavailable	Unavailable	1 / 1
2026-08-01	Unavailable	Unavailable	1 / 0
2026-08-02	Unavailable	Unavailable	1 / 1
2026-08-03	Unavailable	Unavailable	1 / 1
2026-08-04	Unavailable	Unavailable	1 / 1
2026-08-05	Unavailable	Unavailable	1 / 1
2026-08-06	Unavailable	Unavailable	1 / 1
2026-08-07	Unavailable	Unavailable	1 / 0
2026-08-08	Unavailable	Unavailable	1 / 1
2026-08-09	Unavailable	Unavailable	1 / 1
2026-08-10	Unavailable	Unavailable	1 / 1
2026-08-11	Unavailable	Unavailable	1 / 0
2026-08-12	Unavailable	Unavailable	1 / 1
2026-08-13	Unavailable	Unavailable	1 / 1
2026-08-14	Unavailable	Unavailable	1 / 0
2026-08-15	Unavailable	Unavailable	1 / 0
2026-08-16	Unavailable	Unavailable	1 / 0
2026-08-17	Unavailable	Unavailable	1 / 0
2026-08-18	Unavailable	Unavailable	1 / 0
2026-08-19	Unavailable	Unavailable	1 / 0
2026-08-20	Unavailable	Unavailable	1 / 0
2026-08-21	Unavailable	Unavailable	1 / 0
2026-08-22	Unavailable	Unavailable	1 / 0
2026-08-23	Unavailable	Unavailable	1 / 0
2026-08-24	Unavailable	Unavailable	1 / 0
2026-08-25	Unavailable	Unavailable	1 / 0
2026-08-26	Unavailable	Unavailable	1 / 0
2026-08-27	Unavailable	Unavailable	1 / 0
2026-08-28	Unavailable	Unavailable	1 / 0
2026-08-29	Unavailable	Unavailable	1 / 0
2026-08-30	Unavailable	Unavailable	1 / 0
2026-08-31	Unavailable	Unavailable	1 / 0
2026-09-01	Unavailable	Unavailable	1 / 0
2026-09-02	Unavailable	Unavailable	1 / 0
2026-09-03	Unavailable	Unavailable	1 / 0
2026-09-04	Unavailable	Unavailable	1 / 0
2026-09-05	Unavailable	Unavailable	1 / 0
2026-09-06	Unavailable	Unavailable	1 / 0
2026-09-07	Unavailable	Unavailable	1 / 0
2026-09-08	Unavailable	Unavailable	1 / 0
2026-09-09	Unavailable	Unavailable	1 / 0
2026-09-10	Unavailable	Unavailable	1 / 0
2026-09-11	Unavailable	Unavailable	1 / 0
2026-09-12	Unavailable	Unavailable	1 / 0
2026-09-13	Unavailable	Unavailable	1 / 0
2026-09-14	Unavailable	Unavailable	1 / 0
2026-09-15	Unavailable	Unavailable	1 / 0
2026-09-16	Unavailable	Unavailable	1 / 0
2026-09-17	Unavailable	Unavailable	1 / 0
2026-09-18	Unavailable	Unavailable	1 / 0
2026-09-19	Unavailable	Unavailable	1 / 0
2026-09-20	Unavailable	Unavailable	1 / 0
2026-09-21	Unavailable	Unavailable	1 / 0
2026-09-22	Unavailable	Unavailable	1 / 0
2026-09-23	Unavailable	Unavailable	1 / 0
2026-09-24	Unavailable	Unavailable	1 / 0
2026-09-25	Unavailable	Unavailable	1 / 0
2026-09-26	Unavailable	Unavailable	1 / 0
2026-09-27	Unavailable	Unavailable	1 / 0
2026-09-28	Unavailable	Unavailable	1 / 0
2026-09-29	Unavailable	Unavailable	1 / 0
2026-09-30	Unavailable	Unavailable	1 / 0
2026-10-01	Unavailable	Unavailable	1 / 0
2026-10-02	Unavailable	Unavailable	1 / 0
2026-10-03	Unavailable	Unavailable	1 / 0
2026-10-04	Unavailable	Unavailable	1 / 0
2026-10-05	Unavailable	Unavailable	1 / 0
2026-10-06	Unavailable	Unavailable	1 / 0
2026-10-07	Unavailable	Unavailable	1 / 0
2026-10-08	Unavailable	Unavailable	1 / 0
2026-10-09	Unavailable	Unavailable	1 / 0
2026-10-10	Unavailable	Unavailable	1 / 0
2026-10-11	Unavailable	Unavailable	1 / 0
2026-10-12	Unavailable	Unavailable	1 / 0
2026-10-13	Unavailable	Unavailable	1 / 0
2026-10-14	Unavailable	Unavailable	1 / 0
2026-10-15	Unavailable	Unavailable	1 / 0
2026-10-16	Unavailable	Unavailable	1 / 0
2026-10-17	Unavailable	Unavailable	1 / 0
2026-10-18	Unavailable	Unavailable	1 / 0
2026-10-19	Unavailable	Unavailable	1 / 0
2026-10-20	Unavailable	Unavailable	1 / 0
2026-10-21	Unavailable	Unavailable	1 / 0
2026-10-22	Unavailable	Unavailable	1 / 0
2026-10-23	Unavailable	Unavailable	1 / 0
2026-10-24	Unavailable	Unavailable	1 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	2	0	0
2026-06-01	2	0	0
2026-07-01	2	0	0
2026-08-01	2	0	0
2026-09-01	2	0	0
2026-10-01	2	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Net cash used in operations stays below $17 million in H1 2026Published status: Broken
EPS loss narrows toward -$0.25 next quarterPublished status: Under Pressure
Manage $31.25 million estimated loss from securities litigationDirect metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.8%Typical daily move · historical

Downside history

-73.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Filana Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making clinical-development story rather than an established earnings compounder. The long-term thesis is marked intact, but confidence is low and the evidence base is limited.

What's priced into Filana Therapeutics Inc

The available valuation signal describes FLNA as cheap versus peers, while model confidence is low. The priced-in evidence points to a turbulent sector regime, not a broader combination of expensive valuation, weak fundamentals, and sector turbulence.

What the fundamentals likely do

Near term, management has continued scientific publications and community engagement around the TSC-related epilepsy program. Cash fell from $95.5 million at 2025-Q4 to $82.7 million at 2026-Q2, and management projects $36 million to $40 million in unrestricted cash at year-end 2026. The latest recorded earnings event was a beat, but a new litigation filing and a recent listing-rule notice add risk, and the next print is flagged for monitoring.

What Filana Therapeutics Inc hinges on

Over the multi-year view, the thesis hinges on advancing the epilepsy program while managing cash and liquidity. Near term, a guidance cut would be a meaningful negative, while continued strength from healthcare bellwethers could support sector momentum. A weakening jobs trend could add recession concerns, though the evidence does not establish how these factors would affect FLNA specifically.